Plain-English translation of NCT05710198 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing whether citicoline eye drops can help protect your eyes and slow vision loss in open-angle glaucoma. Even when eye pressure is controlled with standard treatment, some people's vision continues to decline. This study looks at whether citicoline—a molecule that may protect nerve cells in the eye—can help prevent further vision loss when added to your regular glaucoma treatment.
Standard glaucoma treatments control eye pressure very well, but some patients still lose vision over time. Researchers believe this medication might protect the nerve cells in the eye from damage, similar to how other treatments work for other nerve diseases.
You likely qualify if…
You likely don't qualify if…
You would be randomly assigned to receive either the citicoline eye drops or placebo eye drops—one drop three times daily for 3 years. You'll continue taking your regular glaucoma medication as prescribed. At regular clinic visits, your eye pressure and vision will be monitored, and you'll have vision field tests to track any changes. You cannot switch treatments once assigned, and you'll need to stop any other similar nerve-protective treatments before starting the study.
AI-generated summary from trial data · Jun 9, 2026 · Not medical advice
Italy